Breaking News

COVID-19 Vaccine Candidate Combining Interleukin-12 with an Enhanced SARS-CoV-2 Spike Protein

January 28, 2021 • 12:40 pm CST
(Vax Before Cancer)

OncoSec Medical Incorporated announced on January 27, 2021, that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19.

This clinical trial, entitled, CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19, will address safety and anti-viral immunological responses with the combination of a DNA-encodable stabilized SARS-CoV-2 spike glycoprotein and OnocSec's cancer immunotherapy candidate, TAVO™ (tavokinogene telseplasmid), a potent and well-characterized plasmid-based IL-12 cytokine.

Medical Review by